[Side effects of sorafenib and countermeasures]
Masashi Nakayama1, Yasuyuki Arai, Kazuo Nishimura
1The Department of Urology, Osaka Medial Center for Cancer and Cardiovascular Diseases.
Hinyokika Kiyo. Acta Urologica Japonica
|December 21, 2012
Summary
Sorafenib administration over 400 mg/day for one month improved progression-free survival (PFS) in advanced renal cell carcinoma (RCC) patients. Managing sorafenib side effects is crucial to avoid dose reduction or treatment withdrawal.
Area of Science:
- Oncology
- Pharmacology
- Nephrology
Background:
- Advanced renal cell carcinoma (RCC) presents significant treatment challenges.
- Sorafenib is a targeted therapy used for advanced RCC.
- Maintaining optimal drug dosage is critical for treatment efficacy.
Purpose of the Study:
- To review the side effects of sorafenib in advanced RCC patients.
- To discuss countermeasures for managing sorafenib-induced side effects.
- To highlight the importance of dose management for prolonged progression-free survival.
Main Methods:
- Review of clinical data on sorafenib treatment in Japanese RCC patients.
- Analysis of sorafenib dosage and its correlation with progression-free survival (PFS).
- Identification and categorization of common sorafenib side effects and their management strategies.
Main Results:
- Administration of sorafenib exceeding 400 mg/day for one month was associated with prolonged PFS in Japanese advanced RCC patients.
- Effective management of side effects is essential to prevent treatment discontinuation or dose reduction.
- Specific side effects and their corresponding countermeasures are detailed.
Conclusions:
- Optimizing sorafenib dosage and proactively managing side effects can improve treatment outcomes in advanced RCC.
- Preventing dose reduction or withdrawal through effective side effect management is key to maximizing PFS.
- This review provides practical guidance for clinicians managing sorafenib therapy in RCC.
More Related Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.0K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
316
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
316
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
01:16Kidney Transplant III: Nursing Management
287
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
287
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
01:11Renal Failure: Dose Adjustments
401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
516
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
516